Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna is ready for a post-pandemic world.

Is Moderna a Post-Pandemic Buy?

BioNTech SE

Novavax

Whether the pandemic is over or not, plenty of people are still looking for protection against COVID-19.

Vaccine Stocks: Down but Not Out?

Pfizer

It's a mixed day for the stock market, but it's not a good day for vaccine stocks. Across the board, these names are getting sold.

Why Are Vaccine Stocks MRNA, PFE, NVAX, BNTX Down Today?

"The pandemic is over. We still have a problem with COVID. We're still doing a low of work on it. But the pandemic is over," Biden said.

Moderna, BioNTech, and Novavax plunge after President Biden says the COVID-19 pandemic 'is over'

Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with "60 Minutes" that aired on Sunday. Moderna Inc. MRNA, -9.41% fell 9.2%, Pfizer Inc. PFE, -1.76% was down 1.7% and its German partner BioNTech SE BNTX, -9.15% was down 8.4%.

Vaccine stocks Pfizer, BioNTech, Moderna and Novavax slide after Biden says pandemic is over

BioNTech SE - ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) are all trading lower during Mo

Why BioNTech, Moderna And Novavax Shares Are Diving

Lovesac Company

Pubmatic

Investment banks still have high expectations for these stocks.

3 Beaten-Down Growth Stocks That Could Soar 60% to 188%, According to Wall Street

The World Health Organization list of Vaccine makers, rapid antigen test manufacturers, and therapeutics were bundled together as a participants group for coming price-range-forecast comparison. The forecasts are near-term (3-5 months only) derived from necessary hedging actions to protect Market-Makers' (short) shares borrowed to supply-balance buyers' demand volumes in block trade market orders from “institutions”.

Moderna And Covid-19 Stocks: Market-Maker Stock Price Range Forecasts

Wall Street thinks the bear market has pushed this top biotech stock down too far.

Here's Why Wall Street Is Super Bullish on Moderna Stock

Amazon

CRISPR Therapeutics

Etsy

Intuitive Surgical

These stocks have what it takes to deliver lasting gains down the road.

If You've Got $5,000, Buying These 5 Top Stocks Right Now Would Be a Genius Move

A possible vaccine supply deal with China has investors piling into the biotech's shares.

Why Moderna Stock Is on Fire Today

The vaccine maker's stock has been in search of a catalyst. Selling Covid-19 vaccines to the world's most populous country could provide one.

Moderna Stock Surges. China Would Be a Big Market.

Moderna wants to conquer a virus we all know pretty well.

What's Moderna's Next Billion-Dollar Market? The Answer May Surprise You.

Moderna Inc has talked with the Chinese government about supplying COVID-19 vaccines, but no decision has been made, CEO Stephane Bancel said on Wednesday.

Moderna open to supplying COVID vaccines to China, CEO says

Moderna, Inc. (NASDAQ:MRNA ) Morgan Stanley 20th Annual Global Healthcare Conference September 13, 2022 10:00 AM ET Company Participants Stephen Hoge - President Conference Call Participants Matthew Harrison - Biotech Analyst at Morgan Stanley Matthew Harrison Good morning everybody. Thanks for joining us for the next session.

Moderna, Inc. (MRNA) Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)

Two trends appear to be working against Moderna right now.

1 Picture That Sums Up Moderna's Biggest Problem

Moderna Inc. MRNA, +0.71% said Monday the Japanese regulator has approved a partial change to its new drug application for its omicron-targeting COVID booster, MRNA-1273.214. The approval from the Ministry of Health, Labour and Welfare is based on data from a Phase 2/3 trial in which the booster met all primary endpoints, including superior neutralizing antibody response against omicron compared to the currently approved dose of Spikevax in previously uninfected trial participants.

Moderna says Japan regulator has approved partial change to NDA for its omicron-targeting COVID booster

CAMBRIDGE, MA / ACCESSWIRE / September 12, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.214 (Spikevax Bivalent Original/Omicron BA.1). Spikevax Bivalent Original/Omicron contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant BA.1.

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Moderna's recent prediction should lift one of investors' biggest fears.

This 1 Number Could Completely Change Your Opinion of Moderna

A prognosticator is particularly hopeful for the company's planned triple vaccine.

Why Moderna Stock Triumphed on Thursday

Pfizer, Moderna, and Novavax all had a rough month in August.

Here's Why These Top 3 COVID-19 Vaccine Stocks Broke Down in August

Vaccine maker Moderna Inc's chief commercial officer (CCO) said on Thursday that the size of the future COVID-19 vaccine market in the United States could be in the range of $5.2 billion to $12.9 billion, depending on the price of shots and who is eligible to receive them.

U.S. COVID-19 vaccine market could be up to $13 billion-Moderna exec

Put options are a way to generate yield with downside protection. MRNA's high volatility makes selling options more attractive.

Put Option Strategy To Generate 11.2% Yield On Cash Or Own Moderna At $82

Repligen

These companies bring different strengths and opportunities to a stock portfolio.

2 Top Healthcare Stocks to Buy for September

Moderna Inc  (NASDAQ:MRNA) received an upgrade from Deutsche Bank to "buy" from "hold" this morning, as well as a price-target hike to $165 from $155.

News for Moderna Stock (MRNA)